Comments for Momenta Pharma: Timing Uncertain, Approval Likely for M-Enoxaparin at http://www.biomedreports.com , comment 1 to 6 out of 6 comments http://www.biomedreports.com Wed, 08 Feb 2012 18:02:23 +0100 FeedCreator 1.7.3 http://www.biomedreports.com/2009100612126/momenta-pharma-timing-uncertain-approval-likely-for-m-enoxaparin.html#comment-1063 Mike,have ever looked at Amarin inc.(AMRN)?. Amarin is a Irish-based pharmaceutical company involved in the development and marketing of Omega-3 therapeutic products used in the treatment of Huntingthon disease ( fase III ended) and mixed hyperlipoied disease ( fase III ending this 4Q ) = very big market .I HAVE it still 3 years and only want to know about a second professional opinion. I bought the first at 25 $!!! ( = 10 times 2.5 $ / reverse share splitt ) - joris vandereycken Wed, 07 Oct 2009 03:03:49 +0100 http://www.biomedreports.com/2009100612126/momenta-pharma-timing-uncertain-approval-likely-for-m-enoxaparin.html#comment-1053 The IHUB forum / info for MNTA is a good resource that includes both objective info and opinions. MNTA is a real company (market cap near $400 million, share price just under 10 bucks) with a valuable technology platform, well-defined / three-part business model, and a major pending catalyst at the FDA so I am not worried about paid pumpers, but I have not used the site for other stocks so I will keep the previous warning comments in mind if I return to the site for other companies. - Mike Havrilla Tue, 06 Oct 2009 12:56:37 +0100 http://www.biomedreports.com/2009100612126/momenta-pharma-timing-uncertain-approval-likely-for-m-enoxaparin.html#comment-1052 agreed. be careful of ihub, some are filled with many pumpers!! - Genvecio Pirate Tue, 06 Oct 2009 10:55:36 +0100 http://www.biomedreports.com/2009100612126/momenta-pharma-timing-uncertain-approval-likely-for-m-enoxaparin.html#comment-1050 Pitt4Rx, Momenta referenced the more stringent USP standards for heparin and were confident that M-Enoxaparin would meet these requirements. Also, Momenta has a good track record working with the FDA in the previous tainted heparin crisis and the partnership with Sandoz gives them the global reach / resources of Novartis. Momenta is clearly the most leveraged play on generic approval for Lovenox, since TEVA is about 100X larger and Watson about 10X larger in terms of market cap. The six-month generic exclusivity period expired in April for the first-to-file company so there are no legal impediments for the launch of M-Enoxaparin; although Sanofi could still choose to market an authorized generic. - Mike Havrilla Tue, 06 Oct 2009 08:32:29 +0100 http://www.biomedreports.com/2009100612126/momenta-pharma-timing-uncertain-approval-likely-for-m-enoxaparin.html#comment-1049 "The InvestorsHub page / forum for Momenta is an excellent resource for in-depth and current overviews on the Company, including several valuation scenarios for the stock." Those iHub pages are in the control of Pumpers, and it has been going on for 3 years now. Caveat Vendor ! - DNDN Pirate Tue, 06 Oct 2009 08:14:02 +0100 http://www.biomedreports.com/2009100612126/momenta-pharma-timing-uncertain-approval-likely-for-m-enoxaparin.html#comment-1046 Mike, Do you think Lovenox and whichever generic approved will increase in use with the new heparin dosing restrictions (potency 90%)? Therefore making MNTA, TEVA, and WPI all potential big winners of becoming the authorized generic for 6 month exclusivity. - Pitt4Rx Tue, 06 Oct 2009 07:35:29 +0100